Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease

Inclusion Criteria: * documented chronic (at least 6 months) HCV Genotype1 (GT1) and Genotype 4 (GT4) infection * Mono infected by HCV or co-infected by HCV and HIV * Have an HCV treatment status corresponding to one of the following: 1. Treatment-naïve: Naïve to all anti-HCV treatment 2. Prior interferon or pegylated interferon + ribavirin treatment failure (null responders, partial responders, relapsers) 3. Prior Interferon (IFN) or pegylated (PEG)-IFN + ribavirin + telaprevir or boceprevir or simeprevir treatment failures 4. Prior sofosbuvir based therapy failures 5. Pegylated interferon ribavirin intolerant * Have CKD defined as: Subjects with glomerular filtration rate (GFR) ≤30 ml/min who are non-dialysis dependent (NDD) or have been on hemodialysis (HD) for at least 3 months (including subjects awaiting kidney transplant and subjects with failed kidney transplants no longer on immunosuppressant therapy). Exclusion Criteria: * none